COVID-19 and AKI [COVID-19]
Research type
Research Study
Full title
Study of the Treatment and Outcomes in critically ill patients with COVID-19 and risk of acute kidney injury
IRAS ID
283672
Contact name
Marlies Ostermann
Contact email
Sponsor organisation
Guy's & St Thomas' NHS Foundation Hospital
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Since the outbreak of coronavirus disease 2019 (COVID-19) in the UK, more than 25,000 patients have died. Acute kidney failure is particularly common in critically ill patients with COVID-19. The exact reasons are not clear. \nPatients who develop kidney failure have an increased risk of dying, especially if acute dialysis treatment is needed. According to the most recent national report, 75% of patients who needed treatment with a ventilator and dialysis treatment died in the Intensive Care Unit (ICNARC report from 30th April 2020). \nDetailed information about the risk factors, contributing factors and management is urgently needed to improve the understanding of this new illness, to inform management and to help designing future research studies. This project aims to address this urgent need. This is a single centre retrospective and prospective data study run at Guy’s and St Thomas’ NHS Foundation trust.\n\nAt the end of UK study we will share our results through a collaboration with Harvard University (US). This collaboration will increase the data, improve the conclusions, increase the scientific value, and allow us to compare UK and US data.\n
REC name
Wales REC 4
REC reference
20/WA/0175
Date of REC Opinion
3 Jun 2020
REC opinion
Favourable Opinion